SOURCE AcelRx Pharmaceuticals, Inc.
AcelRx Announces Primary Endpoint Met In Phase 3 Non-Inferiority Study Of Sublingual Sufentanil NanoTab® PCA System Vs. IV PCA Morphine For Post-Operative Pain
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts